2-Methyl-1--butanon-(3) | 21909-40-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-Methyl-1--butanon-(3)
• 英文别名: 4-(1H-indol-3-yl)-3-methylbutan-2-one
• CAS: 21909-40-0
• 化学式: C₁₃H₁₅NO
• 分子量: 201.268
• InChiKey: FBCBDJFLGHJPQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  32.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Methyl-1--butanon-(3) 在 羟胺 、 甲基磺酰氯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  β-3-吲哚基酮肟合成螺[indoline-3,2'-pyrrolidine]衍生物

  摘要：

  螺[indoline-3,2'-pyrrolidine]衍生物是由β-3-吲哚基酮肟通过用甲磺酰氯和三乙胺通过吲哚环的3-位和肟氮之间的键形成来制备的。这些二氮杂螺环很容易转化为相应的螺羟吲哚衍生物。

  DOI：

  10.1246/cl.2004.26

文献信息

• PROCESS FOR THE PREPARATION OF ASYMMETRICAL BIS(THIOSEMICARBAZONES)
  申请人：The University of Melbourne

  公开号：US20150353487A1

  公开（公告）日：2015-12-10

  The present invention relates to a method of making asymmetrical bis(thiosemicarbazones), compounds useful as synthetic intermediates in the method, new bis(thiosemicarbazones) that can be readily accessed by use of the method and methods of treatment and imaging utilising some of the new bis(thiosemicarbazones).
• COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING CD95-MEDIATED CELL MOTILITY
  申请人：INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：US20210238143A1

  公开（公告）日：2021-08-05

  The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLCγ1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells. Thus, the present invention relates to compounds of formula (A) as defined in the present text, to a pharmaceutical composition comprising said compounds in a pharmaceutically acceptable medium and to the use of these compounds and compositions as medicament, in particular for their use in the reduction or treatment of the above-mentioned pathologies, and in particular in the treatment of cancers and autoimmune inflammatory disease such as systemic lupus erythematosus, inflammatory condition and Th17-mediated disease.
• Synthesis of Spiro[indoline-3,2′-pyrrolidine] Derivatives from β-3-Indolyl Ketone Oximes
  作者：Kenichi Tanaka、Yutaka Mori、Koichi Narasaka

  DOI：10.1246/cl.2004.26

  日期：2004.1

  Spiro[indoline-3,2'-pyrrolidine] derivatives were prepared from β-3-indolyl ketone oximes by treatment with methanesulfonyl chloride and triethylamine via the bond formation between 3-position of the indole ring and oximenitrogen. These diazaspirocycles were readily transformed to the corresponding spiro oxindole derivatives.

  螺[indoline-3,2'-pyrrolidine]衍生物是由β-3-吲哚基酮肟通过用甲磺酰氯和三乙胺通过吲哚环的3-位和肟氮之间的键形成来制备的。这些二氮杂螺环很容易转化为相应的螺羟吲哚衍生物。